Trial Filter
BETAAn intelligent search tool for clinical trials
Combination External Radiation and 177Lu-DOTATATE for Large Gastrointestinal Neuroendocrine Tumors: A Single Arm Pilot Clinical Trial
This phase I trial tests the safety and effectiveness of stereotactic body radiation therapy (SBRT) followed by 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in treating patients with large well-differentiated grade 1-2 digestive system neuroendocrine tumors that cannot be removed by surgery (unresectable). SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body. The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. 177Lu-DOTATATE is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. 177Lu-DOTATATE builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving PRRT after SBRT may reduce the chances of the disease returning or getting worse, compared to the standard treatment of PRRT alone.
Eligibility Criteria
Inclusion Criteria
- 1Male or female
- 2Age ≥ 18 years
- 3Patient must be able to provide study specific informed consent
- 4Pathologically confirmed neuroendocrine tumor fulfilling all of the following criteria
- 5Well-differentiated, grade 1-2
- 6Unresectable (prior resection is allowable), verified by tumor board or surgical oncology (surg onc)
- 7Progression after one or two prior lines of systemic therapy
- 8Somatostatin-receptor positive disease as determined by positive radiotracer-labeled DOTATATE PET/CT scan (modified Krenning score 3+)
- 9One or more large lesions measuring 3 or more cm on contrast-enhanced CT or MRI
- 10Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- 11Estimated glomerular filtration rate (GFR) \> 30 mL/min (within 90 days prior to study registration)
- 12Total bilirubin ≤ 3 x upper limit of normal (within 90 days prior to study registration)
- 13Albumin \> 30 g/L (within 90 days prior to study registration)
- 14White blood cell (WBC) ≥ 2,000 cells/mm\^3 (within 90 days prior to study registration)
- 15Platelets ≥ 70000 cells/mm\^3 (within 90 days prior to study registration)
- 16Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin \[Hgb\] ≥ 8.0 g/dl is acceptable.) (within 90 days prior to study registration)
Exclusion Criteria
- 1Any prior radiation therapy including prior PRRT, external radiation, or Yttrium-90 radioembolization to the same site/region
- 2Contraindications to radiation therapy including inflammatory bowel disease, systemic sclerosis, etc.
- 3Brain metastases or any metastases extending into the spinal canal
- 4Unable to obtain confirmation of payment coverage for any planned radiation treatment
Locations
2 sites participating in this study
Emory University Hospital Midtown
Atlanta, Georgia 30308
Pretesh Patel, MD
Emory University Hospital
Atlanta, Georgia 30322
Pretesh Patel, MD